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The deregulated kinase activity of p210-BCR/ABL oncoproteins, hallmark of chronic myelogenous leukaemia (CML), induces and
sustains the leukaemic phenotype, and contributes to disease progression. Imatinib mesylate, a BCR/ABL kinase inhibitor, is effective
in most of chronic phase CML patients. However, a significant percentage of CML patients develop resistance to imatinib and/or still
progresses to blast crisis, a disease stage that is often refractory to imatinib therapy. Furthermore, there is compelling evidence
indicating that the CML leukaemia stem cell is also resistant to imatinib. Thus, there is still a need for new drugs that, if combined with
imatinib, will decrease the rate of relapse, fully overcome imatinib resistance and prevent blastic transformation of CML. We recently
reported that the activity of the tumour suppressor protein phosphatase 2A (PP2A) is markedly inhibited in blast crisis CML patient
cells and that molecular or pharmacologic re-activation of PP2A phosphatase led to growth suppression, enhanced apoptosis,
impaired clonogenic potential and decreased in vivo leukaemogenesis of imatinib-sensitive and -resistant (T315I included) CML-BC
patient cells and/or BCR/ABL
þ myeloid progenitor cell lines. Thus, the combination of PP2A phosphatase-activating and BCR/ABL
kinase-inhibiting drugs may represent a powerful therapeutic strategy for blast crisis CML patients.
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The equilibrium between kinase and phosphatase signals is
essential for the correct control of normal cell survival, prolifera-
tion and differentiation (Hunter, 1995). In fact, aberrant activity of
cellular kinases has been detected in many cancers, including
leukaemias. Among the different oncogenic kinase-driven neopla-
sia in which altered protein phosphorylation represents the
molecular hallmark of the disease, the p210-BCR/ABL oncopro-
teins of the chronic myelogenous leukaemia (CML), can be
considered the best example of an oncogene with constitutive
tyrosine kinase activity (Calabretta and Perrotti, 2004).
CML, BCR/ABL AND IMATINIB
CML is a clonal disorder of the pluripotent haematopoietic stem
cells and is clinically characterised by two distinct stages, a
protracted myeloproliferative disorder termed chronic phase
(CML-CP) that progresses to a rapidly fatal blast crisis (CML-
BC), which can have either myeloid or lymphoid features
(Calabretta and Perrotti, 2004). Hallmark of CML is the presence
of the Philadelphia chromosome (Ph
1), product of the reciprocal
translocation between chromosome 9 and chromosome 22,
t(9;22)(q34;q11). The translocation results in the fusion of the
BCR to the c-ABL gene. In CML, the BCR/ABL fusion gene encodes
for a 210kDa protein designated as p210
BCR/ABL. It has been well
established that the sole expression of p210-BCR/ABL is sufficient
for the induction of chronic phase CML, and growing evidence
gives to BCR/ABL a central role also in CML progression into blast
crisis (reviewed by Calabretta and Perrotti 2004). In fact, along
with other frequent genetic and molecular abnormalities (e.g.
double Ph
1 chromosome, p53 inactivation) (Johansson et al, 2002),
increased expression and activity of the BCR/ABL oncoprotein is
frequently observed during CML disease progression and in blast
crisis CML (Elmaagacli et al, 2000; Jamieson et al, 2004; Barnes
et al, 2005b), and sustained BCR/ABL expression in myeloid
progenitor cell lines induces phenotypic changes (i.e. differentia-
tion arrest) characteristic of CML-BC (Perrotti et al, 2002). The
ability of BCR/ABL to induce and sustain the leukaemic phenotype
depends on its unrestrained tyrosine kinase activity (reviewed by
Calabretta and Perrotti, 2004), which is essential for the recruit-
ment and activation of multiple pathways that transduce
oncogenic signals leading to growth factor-independent prolifera-
tion, increased survival and altered differentiation (Perrotti et al,
2002) of myeloid precursors. In fact, the pleiotropic effect of BCR/
ABL transformation is mostly dependent on post-translational
modifications (e.g. phosphorylation) of signalling molecules, like
those involved in the RAS/MAPK, PI3K/Akt and STATs pathways,
which control cell growth, survival and differentiation of
haematopoietic cells by modulating the expression and/or activity
of downstream effectors (Melo and Deininger, 2004; Perrotti et al,
2005) (Figure 1). In blast crisis, increased expression of the BCR/
ABL oncoprotein accounts for the block of differentiation,
inactivation of factors with tumour suppressor activity and
decreased genomic stability of the Ph
1 blasts (Perrotti et al,
2002; Skorski, 2002; Trotta et al, 2003; Calabretta and Perrotti,
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expression is not only a characteristic of CML-CP but also of
CML-BC; however, BCR/ABL-independent mechanisms also seem
to contribute to disease progression and imatinib resistance in
some CML cases (Donato et al, 2003; Dai et al, 2004).
Being the deregulated BCR/ABL kinase activity the cause of
CML, targeting its catalytic domain was the most rationale
approach for the rational development of small molecules that
inhibit ABL kinase activity. Imatinib mesylate (Gleevec, Novartis
Basel, Switzerland; STI571), a Kit, Abl and PDGFR inhibitor,
induces apoptosis of the Ph
1 CML progenitors by suppressing the
ability of BCR/ABL to phosphorylate substrates through compe-
titive inhibition at the BCR/ABL ATP binding site (Druker et al,
1996). The development of the BCR/ABL tyrosine kinase inhibitor
imatinib mesylate (Gleevec; formerly STI571) as the treatment of
choice for chronic phase CML and its remarkable therapeutic
effects suggest that blast crisis transition will be postponed for
several years in the majority of CML patients (Deininger et al,
2005a; Roy et al, 2006). However, the persistence of BCR/ABL
transcripts in a cohort of patients with complete cytogenetic
response (Hughes et al, 2003) and the resistance of the primitive
CML stem cell to imatinib treatment (Copland et al, 2006) raises
the possibility that treatment with imatinib alone might delay but
not prevent disease progression. Furthermore, most of the CML
patients in the accelerated and blastic phases of the disease are
either refractory or develop resistance to imatinib monotherapy
(Deininger et al, 2005a). In these CML-BC patients, imatinib
resistance often depends on reactivation of BCR/ABL tyrosine
kinase activity via mechanisms involving BCR/ABL overexpres-
sion, gene amplification or mutations that suppress imatinib-
mediated kinase inhibition (i.e. E255V and G250E) or disrupt
imatinib binding (i.e. T315I) (Shah and Sawyers, 2003). Thus,
development of imatinib resistance appears to predispose to
blastic transformation. Although new phase 1 clinical trials with
the dual Src/Abl inhibitor dasatinib (BMS-354825) and the
selective Abl inhibitor AMN107 show encouraging results (O’Hare
et al, 2005), as they suppress the activity of most BCR/ABL
mutants (except T315I) (O’Hare et al, 2005), in vitro evidence
suggests that resistance to these new compounds may develop
through mechanisms involving the selection and expansion of
BCR/ABL
þ cell clones carrying the T315I BCR/ABL mutant
(Deininger et al, 2005b). Additionally, dasatinib, like imatinib, is
not effective in the treatment of CML-BC patients (Talpaz et al,
2006), and in killing the most primitive quiescent CML cells
(Copland et al, 2006) and, therefore, it may also be ineffective in
preventing disease progression.
The mechanisms responsible for transition of CML chronic
phase into blast crisis remain poorly understood, although a
reasonable assumption is that the unrestrained activity of BCR/
ABL in haematopoietic stem/progenitor cells is the primary
determinant of disease progression. However, a plausible model
of disease progression predicts that increased BCR/ABL expression
promotes the secondary molecular and chromosomal changes
essential for the expansion of cell clones with increasingly
malignant characteristics, and remains crucial for the malignant
phenotype even in advanced stages of the disease (Calabretta and
Perrotti, 2004). According to this model, CML blast crisis would be
expected to occur only in patients with an imatinib-resistant
disease or in those developing resistance during treatment. Indeed,
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Figure 1 Molecular Effects of PP2A activation on BCR/ABL and its downstream effectors. (Left) BCR/ABL inhibits PP2A activity by (A) inducing hnRNP
A1 that, in turn, enhances SET expression, and (B) inducing PP2Ac Y307 phosphorylation. In BCR/ABL
þ myeloid progenitor cells, suppression of PP2A
phosphatase activity is required for sustained activation of mitogenic and survival signals, in part, mediated by the indicated BCR/ABL downstream effectors.
(Right) Restored PP2A activity, achieved by SET downregulation, PP2Ac overexpression or treatment with PP2A activators (e.g. forskolin or 1,9-dideoxy-
forskolin), impairs in vitro and in vivo wild-type and T315I BCR/ABL leukaemogenesis by antagonising the effects of BCR/ABL on its downstream signal
transducers and promoting BCR/ABL inactivation and proteasome-dependent degradation.
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phase patients is associated with a greater likelihood of disease
progression (Soverini et al, 2005). Interestingly, a direct correla-
tion also seems to exist between levels of BCR/ABL activity and
development of imatinib resistance (Schultheis et al, 2005; Barnes
et al, 2005a). Thus, there is still a need for new drugs that, if used
in combination with the available kinase inhibitors, will decrease
the rate of relapse, prevent blastic transformation of CML and,
perhaps, overcome imatinib resistance. Therefore, a better under-
standing of the biology of CML-BC is necessary to identify
molecular networks that, if appropriately modulated, will simulta-
neously affect the function of BCR/ABL and that of multiple signals
aberrantly activated in CML-BC.
PROTEIN PHOSPHATASE 2A (PP2A),
A PHOSPHATASE WITH TUMOUR SUPPRESSOR
ACTIVITY
Protein phosphatases participate in the normal cell homeostasis by
dephosphorylating substrates, therefore providing a negative
feedback to signals triggered by kinases. Altered phosphatase
and/or kinase activity is often associated to malignant transforma-
tion (Hunter, 1995; Blume-Jensen and Hunter, 2001). Hence, some
protein phosphatases have been classified as tumour suppressors
by virtue of their central role in the regulation of cell growth,
survival and/or differentiation (Parsons, 1998; Janssens et al, 2005;
Ostman et al, 2006).
PP2A, one of the major cellular serine-threonine phosphatase
activity, is a heterotrimeric complex typically consisting of a
catalytic subunit C, a structural subunit PR65/A, which exists in the
isoforms a and b, and an array of different subunit B (divided into
four families B, B0,B 00 and B000) that confers substrate specificity
and target the enzyme to different intracellular location (Janssens
and Goris, 2001; Schonthal, 2001). Moreover, the association of the
catalytic and structural subunit with some B isoforms determines
the tissue- and developmental stage-specific expression patterns to
different PP2A complexes (Martens et al, 2004). PP2A is involved
in almost all of the cellular processes, including signal-transduction
pathways transducing mitogenic and survival signals (e.g. PP2A
negatively regulates the RAS/MAPK and the PI3K/Akt pathways),
transcriptional and translational regulation, DNA replication and
control of cell cycle (Janssens and Goris, 2001; Sontag, 2001).
The ability of PP2A to antagonise cancer development has first
been suggested in the late 1980s when it was described as target of
the tumour promoter okadaic acid; however, only recently, PP2A
received the designation of ‘tumour suppressor’ (Van Hoof and
Goris, 2004; Janssens et al, 2005). In fact, suppression of PP2A
activity appears to be a common event in different human
neoplasia. For example, genetic alterations of the genes encoding
the b-isoform of the structural subunit PP2AA and some of the
regulatory PP2AB subunits have been found in several types of
human cancer (Van Hoof and Goris, 2004; Janssens et al, 2005, and
references therein). Moreover, oncogenic viral proteins, such as
the SV40 virus small-t antigen, inhibit PP2A activity by interacting
with the subunit A of PP2A complexes and displacing various B
subunits (Sontag, 2001). Conversely, overexpression of PP2Ac
reduces Ha-RAS-induced cellular transformation (Baharians and
Schonthal, 1999). As result, loss of PP2A activity leads to
constitutive activation and increased stability of protein kinases
transducing mitogenic and survival signals (e.g. MAPK and AKT)
and protoncogenes (e.g. Myc) (Sontag, 2001; Yuan et al, 2002; Yeh
et al, 2004). Furthermore, the PP2A subunit A per se also has been
described to be genetically or functionally altered in different types
of cancer. Indeed, mutations of PR65/Ab have been reported in
primary lung tumours and in colorectal carcinomas, in which a
gene deletion generates a truncated A subunit that is unable to
interact with the PP2Ac catalytic subunit (Wang et al, 1998).
Similarly, loss or reduced expression of PR65 has been detected in
human gliomas and breast cancer cell lines (Colella et al, 2001;
Suzuki and Takahashi, 2003). Accordingly, in immortalised but not
tumorigenic cells, expression of PR65/Aa mutants defective in
binding to other PP2A subunits partially suppressed endogenous
PP2A-Aa expression, activated the AKT pathway and promoted
tumour formation in immunodeficient mice (Chen et al, 2005b).
Thus, mutations of the PR65/A subunits might contribute to
cancer development by altering the PP2A multimeric composition
and, therefore, its phosphatase activity. Alterations in the
quaternary structure of PP2A also appears to have a crucial
function in cells transformation and tumour development, as
different B subunits have been found either aberrantly expressed
in human cancers or displaced by the interaction of PR65/A with
the SV40 small-t antigen, and by mutations of the PP2A A subunits
(Janssens et al, 2005). For example, the B56g subunit is highly
expressed in numerous human malignant melanoma cells com-
pared to normal epidermal melanocytes (Francia et al, 1999).
Importantly, B56g participates also in the regulation of the Wnt/
b-catenin signalling, a pathway important in the control of cell
proliferation and self-renewal of the cancer stem cell. In fact, B56g
directly interacts with APC in the b-catenin/axin/GSK-3b complex
and induces b-catenin inactivation/degradation (Seeling et al,
1999). Moreover, the catalytic subunit of PP2A has been found
associated to axin (Li et al, 2001), suggesting that PP2A:B56 is part
of the b-catenin degradation complex.
In transformed cells, inactivation of PP2A phosphatase and,
therefore, loss of its tumour suppressor activity may not only be a
consequence of genetic alterations (i.e. mutations) and/or aberrant
expression of a specific PP2A subunit, but it could also derive from
aberrant activation of signal-transduction pathways leading to
post-translational modifications of the PP2A catalytic subunits
and/or increased expression of molecules that act as general
physiological inhibitors of PP2A phosphatase activity (Janssens
and Goris, 2001). In fact, activation of Jak2 (Yokoyama et al, 2001)
and/or src (Chen et al, 1992) kinases results in the suppression of
PP2A phosphatase activity through a mechanism that involves the
phosphorylation of the PP2Ac subunits on tyrosine 307. Likewise,
expression of pp32 (I1PP2A) and SET (I2PP2A), two potent
physiologic PP2A inhibitors, suppresses the phosphatase activity
of all holoenzyme forms of PP2A, most likely through direct
binding to the PP2A catalytic subunit (Li et al, 1996; Janssens and
Goris, 2001). Interestingly, SET (also known as I2PP2A, IGAAD or
TAF-Ib) is a nucleus/cytoplasm-localised phosphoprotein over-
expressed in solid tumours and leukaemias (Fornerod et al, 1995;
Carlson et al, 1998). In addition to its activity as an inhibitor of
PP2A, SET is also a potent inhibitor of the tumour suppressor
NM23-H1 (Fan et al, 2003). Notably, SET was described as part of a
fusion gene with the nucleopore complex protein CAN in a patient
with t(6;9)(p23;q34) acute myeloid leukaemia (AML) (Adachi et al,
1994), and it was found associated with the oncoprotein Mll (ALL1,
HRX) in leukaemic cell lines (Adler et al, 1997). Thus, it is intuitive
that genetic (mutations in the gene encoding a specific PP2A
subunits) or functional (e.g. PP2Ac
Y307 phosphorylation, SET
overexpression) inactivation of PP2A may represent a step
required for cancer development and/or progression. Indeed, the
importance of the SET/PP2A interplay in cancer has been recently
investigated in chronic myelogenous leukaemia in which a SET-
mediated inhibition of PP2A phosphatase activity is distinctively
occurring in patients with blast crisis CML (Neviani et al, 2005).
BCR/ABL AND PP2A: THE YIN AND YANG OF BLAST
CRISIS CML
Although the mechanisms responsible for CML disease progres-
sion are still largely unclear, growing evidence suggests that the
phenotype of CML-BC cells depends on the unrestrained activity of
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with tumour suppressor activity (Calabretta and Perrotti, 2004).
Moreover, altered mRNA metabolism appears to play a pivotal role
in blast crisis CML, as mRNA processing, export and translation of
specific mRNAs controlling survival and differentiation of myeloid
progenitors (e.g. Bcl-XL, GCSFR, C/EBPa and b, MDM2 and MYC)
are aberrantly regulated by increased BCR/ABL expression
through the activity of specific mRNA binding proteins (e.g.
TLS/FUS, hnRNP A1, hnRNP E2, La, hnRNP K and CUGBP1)
(Perrotti et al, 1998; Iervolino et al, 2002; Perrotti et al, 2002;
Trotta et al, 2003; Guerzoni et al, 2006; Notari et al, 2006).
Specifically, the mRNA export activity of hnRNP A1, an RNA-
binding protein overexpressed in CML-BC, is required for
cytokine-independent proliferation, survival and tumorigenesis
of acute phase CML blasts and BCR/ABL-expressing myeloid
progenitor cell lines (Iervolino et al, 2002). By Ribonomics
(Tenenbaum et al, 2002), we identified SET as a novel BCR/ABL
target whose mRNA is specifically associated with hnRNP A1
(Figure 1) in Ph
1 K562 cells (Neviani et al, 2005).
The SET/PP2A interplay in CML
SET expression is modestly affected in CML-CP
CD34þ progenitors,
but markedly upregulated in myeloid CML-BC
CD34þ cells in which
it correlates with loss of PP2A phosphatase activity (Neviani et al,
2005). Interestingly, PP2A inactivation is a direct consequence of
increased expression of SET (Figure 1), which is induced by BCR/
ABL in a dose- and kinase-dependent manner and, like BCR/ABL,
progressively increases during transition to blast crisis (Neviani
et al, 2005). In fact, imatinib treatment and SET downregulation
restored PP2A activity back to normal levels. Interestingly, a
portion of PP2Ac is phosphorylated on tyrosine 307 in BCR/ABL-
expressing cells, and PP2A
TYR307 levels decreases upon SET
downregulation or inhibition of BCR/ABL activity (Neviani et al,
2005). Thus, it is possible that BCR/ABL also affects the ability of
PP2A to reactivate itself by autodephosphorylation (Chen et al,
1992) and/or that the SET/PP2A association favours the recruit-
ment of a BCR/ABL-activated tyrosine kinase, which inhibits PP2A
through phosphorylation of the PP2Ac tyrosine 307. Alternatively,
SET overexpression and src and/or Jak2 activity might indepen-
dently contribute to PP2A inactivation in BCR/ABL cells (Figure 1).
Moreover, the PP2A subunit PR65/A, which is also overexpressed
in BCR/ABL
þ cells, may also contribute to PP2A inactivation, as
PR65/A overexpression could sequester the catalytic or variable
subunits or act as a PP2Ac inhibitor (Kamibayashi et al, 1992;
Wera et al, 1995). Interestingly, it was recently reported that
hnRNP A2, an hnRNP with high sequence, structure and function
similarity with hnRNP A1, inhibits PP2A activity upon interaction
with SET (Vera et al, 2006). Because also hnRNP A2 expression is
induced by BCR/ABL (our unpublished observation), the hnRNP
A2/SET-dependent inhibition of PP2A may represent another
mechanism whereby BCR/ABL induces the loss of PP2A function
in CML-BC.
Adverse molecular effects of BCR/ABL and PP2A
As reported above, the tumour-suppressing activity of PP2A
depends on its ability to dephosphorylate several factors regulating
cell cycle progression, proliferation, survival and differentiation
(Sontag, 2001). Remarkably, several targets are shared by BCR/
ABL kinase and PP2A phosphatase. Among these, expression and/
or activity of the PP2A targets Myc, STAT5, MAPK, Akt, BAD and
Rb (Neviani et al, 2005, and references therein) are either essential
for BCR/ABL leukaemogenesis or have been found altered in CML-
BC (Calabretta and Perrotti, 2004, and references therein). In BCR/
ABL-expressing myeloid progenitor 32Dcl3 cells, inhibition of SET
expression and, to a greater extent, forced expression of PP2Ac led
to inhibition of MAPK, STAT5 and Akt phosphorylation,
decreased Myc expression and increased levels of proapoptotic
BAD (Neviani et al, 2005) (Figure 1). Since ectopic SET expression
antagonised the effects of exogenous PP2A, it is possible that, in
CML-BC progenitors, SET-dependent suppression of PP2A activity
represents one of the main mechanisms used by BCR/ABL to
prevent inactivation of mitogenic and survival signals required for
its leukaemogenic activity. The importance of loss of PP2A activity
for CML disease progression is also supported by the ability of
PP2A to induce Rb dephosphorylation (Avni et al, 2003) and
suppress Jak2 kinase, which was found activated in CML-BC (Xie
et al, 2002).
BCR/ABL as target of PP2A activity: role of SHP-1
In imatinib-sensitive and -resistant (T315I included) BCR/ABL cell
lines and in CML-BC
CD34þ patient cells, restoration of PP2A
phosphates activity, achieved either by using chemical PP2A
activators (e.g. forskolin; Feschenko et al, 2002) or by interfering
with the SET/PP2A interplay (i.e. PP2Ac overexpression, SET
knockdown), promotes BCR/ABL tyrosine dephosphorylation
(inactivation) which, in turn, trigger its proteasome-dependent
degradation (Neviani et al, 2005). The ability of PP2A to impair
activity and expression of oncogenic tyrosine kinases is not
unprecedented; in fact, PP2A induces inactivation and promotes
proteolysis of src kinase (Yokoyama and Miller, 2001). Mechan-
istically, BCR/ABL proteolysis appears to depend on the PP2A-
induced activation of the tumour suppressor SHP-1 tyrosine
phosphatase and on the coexistence of BCR/ABL, PP2A and SHP-1
in the same multiprotein complex (Neviani et al, 2005) (Figure 1).
In fact, increased cytokine-independent clonogenic potential and
inability of PP2A to promote BCR/ABL degradation was observed
in BCR/ABL-transduced SHP-1-decifient CD34
þ/lineage-negative
marrow myeloid progenitors cells (Neviani et al, 2005). Interest-
ingly, BCR/ABL dephosphorylation has been also observed in K562
cells overexpressing tyrosine phosphatase PTP1B (LaMontagne
et al, 1998). Although ectopic PTP1B expression impairs
clonogenicity and tumorigenesis of p210-BCR/ABL-transformed
Rat-1 fibroblasts and induces K562 erythroid maturation (LaMon-
tagne et al, 1998); it is still unclear why PTP1B expression is
increased in BCR/ABL-expressing cells (LaMontagne et al, 1998)
and whether PTP1B activity is altered in primary CML progenitors
or changed during disease progression.
The involvement of SHP-1 in the PP2A-induced negative
regulation of BCR/ABL kinase activity and expression is also
supported by the fact that SHP-1 associates with BCR/ABL and its
tyrosine phosphatase activity counteracts BCR/ABL leukaemogenic
potential (Liedtke et al, 1998; Lim et al, 2000). Accordingly,
expression of SHP-1 is diminished in most of leukaemias and
lymphomas, SHP-1 downregulation leads to abnormal cell growth
and SHP-1 activity is suppressed by different oncogenic tyrosine
kinases (e.g. FLT3/ITD and JAK) (Wu et al, 2003; Chen et al,
2005a). Thus, functional inactivation of PP2A by increased BCR/
ABL kinase activity seems to be required for the transduction of
aberrant mitogenic, survival and antidifferentiation signals, and
for the post-translational enhancement of BCR/ABL expression
and oncogenic activity in CML-BC
CD34þ marrow myeloid
progenitors (Figure 1).
Restoration of PP2A activity impairs BCR/ABL
leukaemogenesis: therapeutic effects of the PP2A
activator forskolin
Consistent with the negative effects of PP2A on BCR/ABL
expression and function, restoration of PP2A activity back to
normal levels via SET downregulation, PP2Ac overexpression or
treatment with the potent PP2A activator forskolin (Feschenko
et al, 2002) or with 1,9-dideoxy-forskolin (forskolin derivative that
lacks adenylate cyclase-cAMP- (Seamon and Daly, 1981) activating
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colony formation, inhibits tumorigenesis and restores differentia-
tion of patient-derived myeloid CML-BC
CD34þ cells and/or BCR/
ABL-transformed cell lines, regardless of their degree of sensitivity
to imatinib (Neviani et al, 2005). Notably, the imatinib-, AMN107-
and dasatinib-resistant T315I BCR/ABL
þ cells are also sensitive to
PP2A activation (Neviani et al, 2005). Remarkably, forskolin but
not 1,9-dideoxy-forskolin delayed proliferation of CD34þ normal
marrow cells without inducing either apoptosis or PP2A activity.
Consistent with the in vitro effects of restoration of PP2A
activity, in vivo administration of forskolin and/or 1,9-dideoxy
forskolin severely impacted and efficiently modulated the devel-
opment of wild-type and T315I BCR/ABL-induced acute leukae-
mia-like disease process in immunocompromised mice (Neviani
et al, 2005).
Forskolin, a diterpene extracted from the roots of Coleus
forskohlii, was primarily and extensively studied and used in
rodents and humans for its adenylate cyclase-activating functions
and, more recently, for its ability to activate PP2A. Although the
molecular mechanism underlying PP2A activation by forskolin
(Feschenko et al, 2002) in BCR/ABL-transformed cells is still
largely unclear, it seems that it does not depend on increased
cAMP or PKA activation (Neviani et al, 2005).
Clinical trials demonstrated the low toxicity of the water-soluble
forskolin in the treatment of patients with cardiac dysfunction or
bronchospasm (Wajima et al, 2003; Kikura et al, 2004).
Furthermore, the use of forskolin as an antileukaemogenic agent
is not unprecedented, as it inhibits growth and/or induces
apoptosis of different types of leukaemic cells in vitro (Laneuville
et al, 1992; Moon and Lerner, 2003). However, all of these studies
were all focused on assessing the importance of cAMP in
leukaemogenesis, as they were undertaken when the property of
forskolin as PP2A activator was still unknown.
The in vivo forskolin and 1,9-dideoxy forskolin antileukaemic
activity and the low toxicity are consistent with the long
elimination half-life assessed in healthy individuals and with the
absence of toxicity in mice treated with these compounds (Kikura
et al, 2004; Neviani et al, 2005). Furthermore, the safety and
therapeutic effects of these diterpenes are also suggested by the
prolonged survival of SCID mice transplanted with wild-type or
T315I BCR/ABL cells (50% of mice were alive after 25 weeks of
treatment while untreated leukaemic mice died within 5 weeks),
and by the lack of signs of toxicity or leukaemia after
administration of these compound for 18 (Neviani et al, 2005)
and 25 (our unpublished data) weeks at 4 and 8mgkg
 1week
 1.
Although the ability of forskolin to prevent tumour colonisation
and metastasis was reported previously (Agarwal and Parks, 1983),
our work for the first time underscores the therapeutic relevance of
PP2A-activating drugs in cancer by specifically indicating that
treatment of leukaemic mice with forskolin or 1,9-dideoxy
forskolin remarkably prolongs the lifespan and decreases the
leukaemia burden to a point in which no BCR/ABL
þ cells are
detected in peripheral blood of treated animals (Neviani et al,
2005).
CONCLUSIONS
Because of the central role of PP2A in the regulation of cell growth,
survival and differentiation, it is clear that its loss-of-function
contributes to tumour development and progression. Moreover,
the knowledge that functional inactivation of PP2A tumour
suppressor activity occurs in myeloid blast crisis CML through
the effect BCR/ABL on SET expression, and that re-establishment
of normal PP2A activity antagonises both in vitro and in vivo BCR/
ABL leukaemogenesis (see Figure 1), highlights the importance of
incorporating PP2A activating drugs (e.g. forskolin) in the current
therapeutic protocols for blast crisis and imatinib-resistant (T315I
included) CML. In particular, the association of imatinib or new
ABL-kinase inhibitors with drugs that enhances PP2A phosphatase
activity may represent a successful therapeutic strategy for CML
blast crisis patients that are nonresponsive or develop resistance to
imatinib and, perhaps, for those patients with Ph1 ALL.
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